-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

HIT-and-Run: Challenges in Diagnosis and Management of Heparin-Induced Thrombocytopenia

Program: Education Program
Hematology Disease Topics & Pathways:
Bleeding and Clotting, Clinical Practice (Health Services and Quality), Diseases, Immune Disorders
Saturday, December 7, 2024: 4:00 PM-5:15 PM
Room 28 A-D (San Diego Convention Center)

Description:
In hospitalized patients, the diagnosis and management of heparin induced thrombocytopenia (HIT) is a recurrent challenge. To this end, this session will 1) provide evidence-based practical guidance in the diagnosis and management of suspected and confirmed HIT; 2) classify anti-platelet factor 4 (PF4) antibody mediated disorders (autoimmune HIT), their relationship to heparin exposure, and the role of rapid PF4 and platelet activation assays in diagnosis; and 3) review alternative management strategies when heparin cessation and non-heparin anticoagulants are insufficient in patients who have refractory HIT, experience acute bleeding, or are planned to undergo cardiac surgery. Emphasizing evidence-based strategies, this session will provide practical approaches and system-level interventions for high-quality care.

Chair:
Toyosi Onwuemene, MD, MS, Duke University
Disclosures:
Onwuemene: Sanofi: Honoraria.

In hospitalized patients, the diagnosis and management of heparin induced thrombocytopenia (HIT) is a recurrent challenge. To this end, this session will 1) provide evidence-based practical guidance in the diagnosis and management of suspected and confirmed HIT; 2) classify anti-platelet factor 4 (PF4) antibody mediated disorders (autoimmune HIT), their relationship to heparin exposure, and the role of rapid PF4 and platelet activation assays in diagnosis; and 3) review alternative management strategies when heparin cessation and non-heparin anticoagulants are insufficient in patients who have refractory HIT, experience acute bleeding, or are planned to undergo cardiac surgery. Emphasizing evidence-based strategies, this session will provide practical approaches and system-level interventions for high-quality care.

Jori E. May, MD

Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL

Toyosi Onwuemene, MD, MS

Division of Hematology, Department of Medicine, Duke University, Durham, NC

Marie Scully, MD

University College London, London, ENG, United Kingdom

See more of: Education Program